Login to Your Account

Navitor to further mTORC1 modulators with $33M series B

By Michael Fitzhugh
Staff Writer

Friday, December 18, 2015

A year and a half after landing a $23.5 million series A financing, Navitor Pharmaceuticals Inc. has attracted new investors to a $33 million series B round intended to help it identify a lead candidate in a pipeline of candidates capable of modulating the mammalian target of mTORC1 pathway.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription